Bregua Corp. Maintains Significant Stake in Janux Therapeutics

TL;DR

**Bregua Corp. is still a major holder in Janux Therapeutics, showing confidence.**

AI Summary

Bregua Corporation, a British Virgin Islands entity, filed an amended SC 13G/A on February 1, 2024, indicating its ownership of Janux Therapeutics, Inc. common stock as of December 31, 2023. This filing updates previous disclosures, confirming Bregua's continued significant stake in Janux Therapeutics. For investors, this matters because it shows a major institutional holder is maintaining its position, which can be interpreted as a vote of confidence in the company's future prospects.

Why It Matters

This filing confirms a key institutional investor, Bregua Corporation, is holding onto its shares in Janux Therapeutics, signaling continued belief in the company's value.

Risk Assessment

Risk Level: low — This is an amendment to a passive ownership filing, indicating no immediate change in control or significant new risks.

Analyst Insight

An investor should note that a significant institutional holder is maintaining its position, which could be a positive signal, but this filing alone doesn't provide new information about their future intentions or changes in ownership percentage.

Key Players & Entities

• Bregua Corporation (company) — the reporting person and beneficial owner of Janux Therapeutics shares
• Janux Therapeutics, Inc. (company) — the issuer of the common stock being reported
• British Virgin Islands (company) — place of organization for Bregua Corporation
• December 31, 2023 (date) — the date of the event requiring this filing
• February 1, 2024 (date) — the filing date of the SC 13G/A amendment

FAQ

Filing Documents

• d724857dsc13ga.htm (SC 13G/A) — 38KB
• 0001193125-24-021859.txt ( ) — 40KB

From the Filing

SC 13G/A 1 d724857dsc13ga.htm SC 13G/A SC 13G/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G U NDER T HE S ECURITIES E XCHANGE A CT OF 1934 (A MENDMENT N O . 1) Janux Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 47103J 105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes ). CUSIP No. 47103J 105 13G Page 2 of 5 Pages 1. Names of Reporting Persons Bregua Corporation 2. Check the Appropriate Box if a Member of a Group (see instructions) (a)(b) 3. SEC USE ONLY 4. Citizenship or Place of Organization British Virgin Islands Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 3,830,257 6. Shared Voting Power 0 7. Sole Dispositive Power 3,830,257 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 3,830,257 10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (see instructions) 11. Percent of Class Represented by Amount in Row 9 8.3%(1) 12. Type of Reporting Person (see instructions) CO (1) The percentage is calculated based on 46,262,759 shares of Common Stock outstanding as of December 31, 2023. CUSIP No. 47103J 105 13G Page 3 of 5 Pages Item1. (a) Name of Issuer Janux Therapeutics, Inc., a Delaware corporation (b) Address of Issuers Principal Executive Offices 10955 Vista Sorrento Parkway, Suite 200 San Diego, CA 92130 Item2. (a) Name of Person Filing Bregua Corporation (b) Address of Principal Business Office or, if none, Residence Wickhams Cay, P.O. Box 146, Road Town Tortola, VG 1110, BVI (c) Citizenship British Virgin Islands (d) Title of Class of Securities Common Stock (e) CUSIP Number 47103J 105 Item3. Not applicable Item4. (a) Amount Beneficially Owned: 3,830,257 shares of Common Stock (b) Percent of Class: 8.3% (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote: 3,830,257 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 3,830,257 (iv) Shared power to dispose or to direct the disposition of: 0 Item5. Not applicable Item6. Not applicable CUSIP No. 47103J 105 13G Page 4 of 5 Pages Item7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. Not applicable Item8. Identification and Classification of Members of the Group Not applicable Item9. Notice of Dissolution of a Group Not applicable Item10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. CUSIP No. 47103J 105 13G Page 5 of 5 Pages SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 1, 2024 Date /s/ Klaus Dorner Signature Klaus Dorner, Director of Bregua Corporation Name/Title The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representatives authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature. Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties for

View Full Filing

View this SC 13G/A filing on SEC EDGAR